Gilead Pays ViiV $1.25B Plus Royalties To End HIV Patent Suit
Gilead has agreed to pay $1.25 billion plus royalties to GlaxoSmithKline venture ViiV Healthcare to settle claims Gilead infringed patents with its HIV drug, the companies announced Tuesday, a deal that...To view the full article, register now.
Already a subscriber? Click here to view full article